Amgen is trading at $475.39, up +3.06%, after beating third-quarter revenue and adjusted EPS expectations and raising 2026 guidance. - On November 4, it reported third-quarter revenue of $10.37 billion and adjusted EPS of $6.45, both above analyst expectations. - It raised 2026 revenue guidance to $38.9–$39.7 billion and adjusted EPS guidance to $22.90–$23.70. - Repatha sales rose 37% to $1.085 billion. The broad-market and biotech-sector rally may also be supportive, but the earnings beat and higher guidance are the clearest company-specific catalysts.